Mode
Text Size
Log in / Sign up
Phase 3 N=2,040 Randomized Quadruple-blind Prevention

Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin

Injury of Radial Artery

Enrolled (actual)
2,040
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Radial Artery Occlusion — 13; 13; 10; 13 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Nitroglycerin I (Drug); Placebo I (Drug); Nitroglycerin II (Drug); Placebo II (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Instituto de Cardiologia de Santa Catarina
Primary completion
Oct 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Radial Artery Occlusion
13; 13; 10; 13
SECONDARY
Late Radial Artery Occlusion
9; 9; 7; 9
SECONDARY
Pain Assessment
2.7; 2.4; 2.7; 2.4
SECONDARY
Spasm (Operator Evaluation)
12; 10; 10; 12
SECONDARY
Procedure Duration
1,193.22; 1,216.29; 1,229.83; 1,179.67
SECONDARY
Radiation Exposure
584.52; 591.30; 599.78; 576.09

Summary

The radial approach for a coronary angiography has became popular in several centers because of its simplicity and fewer complications. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation of future use of the radial artery as an access site for catheterization in the future. Several strategies have been used to decrease the incidence of RAO (heparin, patent hemostasis, etc). Nitrates in intra-arterial have been widely studied in prevention of this spasm. Current data show that nitroglycerin intra-arterial at the end of the procedure reduce the incidence of RAO. The hypothesis that use of nitroglycerin at the start of catheterization would have the same effect was not tested.

Eligibility Criteria

Inclusion Criteria

  • Indication for cardiac catheterization;
  • Suitable candidates for transradial approach;
  • Use of 5 or 6 French sheath in the procedure;
  • Signed informed consent.

Exclusion Criteria

  • Unable to tolerate nitrates or known allergy to nitrates;
  • Use of any nitrate, by any route of administration, up to 1 hour before the procedure;
  • ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;
  • Intubated patients (on mechanical ventilation);
  • Complications before or during procedure (cardiac arrest, pulmonary edema, cardiogenic shock, stroke);
  • Prior inclusion in this trial.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03158532). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search